European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 2.34 MB, PDF document

  • Sevtap Arikan-Akdagli
  • Karin Meinike Jørgensen
  • Aleksandra Barac
  • Jörg Steinmann
  • Cristina Toscano
  • Valentina Arsic Arsenijevic
  • Assunta Sartor
  • Cornelia Lass-Flörl
  • Axel Hamprecht
  • Tadeja Matos
  • Benedict R.S. Rogers
  • Inmaculada Quiles
  • Jochem Buil
  • Volkan Özenci
  • Robert Krause
  • Matteo Bassetti
  • Laura Loughlin
  • Blandine Denis
  • Anna Grancini
  • P. Lewis White
  • Katrien Lagrou
  • Birgit Willinger
  • Riina Rautemaa-Richardson
  • Petr Hamal
  • Beyza Ener
  • Tugce Unalan-Altintop
  • Ebru Evren
  • Suleyha Hilmioglu-Polat
  • Yasemin Oz
  • Ozlem Koyuncu Ozyurt
  • Faruk Aydin
  • Filip Růžička
  • Eelco F.J. Meijer
  • Jean Pierre Gangneux
  • Deborah E.A. Lockhart
  • Nina Khanna
  • Clare Logan
  • Ulrike Scharmann
  • Guillaume Desoubeaux
  • Emmanuel Roilides
  • Alida Fe Talento
  • Karin van Dijk
  • Philipp Koehler
  • Jon Salmanton-García
  • Oliver A. Cornely
  • Martin Hoenigl

The objectives of this study were to assess Candida spp. distribution and antifungal resistance of candidaemia across Europe. Isolates were collected as part of the third ECMM Candida European multicentre observational study, conducted from 01 to 07-07-2018 to 31-03-2022. Each centre (maximum number/country determined by population size) included ∼10 consecutive cases. Isolates were referred to central laboratories and identified by morphology and MALDI-TOF, supplemented by ITS-sequencing when needed. EUCAST MICs were determined for five antifungals. fks sequencing was performed for echinocandin resistant isolates. The 399 isolates from 41 centres in 17 countries included C. albicans (47.1%), C. glabrata (22.3%), C. parapsilosis (15.0%), C. tropicalis (6.3%), C. dubliniensis and C. krusei (2.3% each) and other species (4.8%). Austria had the highest C. albicans proportion (77%), Czech Republic, France and UK the highest C. glabrata proportions (25–33%) while Italy and Turkey had the highest C. parapsilosis proportions (24–26%). All isolates were amphotericin B susceptible. Fluconazole resistance was found in 4% C. tropicalis, 12% C. glabrata (from six countries across Europe), 17% C. parapsilosis (from Greece, Italy, and Turkey) and 20% other Candida spp. Four isolates were anidulafungin and micafungin resistant/non-wild-type and five resistant to micafungin only. Three/3 and 2/5 of these were sequenced and harboured fks-alterations including a novel L657W in C. parapsilosis. The epidemiology varied among centres and countries. Acquired echinocandin resistance was rare but included differential susceptibility to anidulafungin and micafungin, and resistant C. parapsilosis. Fluconazole and voriconazole cross-resistance was common in C. glabrata and C. parapsilosis but with different geographical prevalence.

Original languageEnglish
JournalJournal of Infection
Volume87
Issue number5
Pages (from-to)428-437
Number of pages10
ISSN0163-4453
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 The Author(s)

    Research areas

  • C. parapsilosis, Candida, Echinocandin resistance, EUCAST, Fks1, Fluconazole resistance

ID: 375195102